top of page

ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer

Jun 2, 2025
1 min read

Updated: Jun 20, 2025

Chairman and CEO Alessandro Riva describes the computational work that is done to choose the personalized neoantigens for this cancer vaccine, and he describes why head and neck was a good fit to test the therapy out in. Plus, he covers the data and talks about next steps.



In the interview, the number of patients randomized in the trial is misstated. The correct numbers are 17 patients in the TG4050 vaccine arm and 16 patients in the observational arm, as presented at ASCO 2025.


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@Biotech.TV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page